Details of the Drug
General Information of Drug (ID: DMNUQ9P)
| Drug Name |
SKF-89124A
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
F 89124; CHEMBL587; 7-HYDROXY ROPINIROLE; 81654-62-8; 4-[2-(dipropylamino)ethyl]-7-hydroxy-1,3-dihydro-2h-indol-2-one; Skf-18924A; Skf 89124A; Skf 89124; F-89124; AC1Q6M2P; AC1L33CC; SCHEMBL2914813; 4-(2-Di-n-propylaminoethyl)-7-hydroxy-2-(3H)indolone; CTK8D5316; DTXSID60231232; 4-[2-(dipropylamino)ethyl]-7-hydroxy-1,3-dihydroindol-2-one; ZINC5832868; BDBM50019393; 4-(N,N-Dipropyl-2-aminoethyl)-7-hydroxy-2(3H)-indolone hydrochloride; AKOS030547943; 4-(2-di-n-propylaminoethyl)-7-hydroxy-2-(3h)-indolone
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 276.37 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2.3 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 7 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


